How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Oncology Drug Discovery Services Market
- By Service Type: Target Identification and Validation, High Throughput Screening, Lead Optimization, Preclinical Development, Biomarker Discovery
- By Technology Platform: Cell-based Assays, Molecular Docking, Genomics and Proteomics, CRISPR Screening, In Vivo Models
- By Therapeutic Area: Solid Tumors, Hematologic Malignancies, Immuno-oncology, Personalized Oncology, Rare Cancers
- By End User: Pharmaceutical Companies, Biotechnology Firms, Contract Research Organizations (CROs), Academic and Research Institutes, Government Research Laboratories
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Target Identification and Validation leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Oncology Drug Discovery Services Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
Technology Platform 5
Therapeutic Area 5
End User 5
Companies profiled
Charles River Laboratories International Inc.
WuXi AppTec Co. Ltd.
Labcorp Drug Development (Covance)
ICON plc
PPD
Inc. (Thermo Fisher Scientific)
Syneos Health Inc.
Parexel International Corporation
IQVIA Holdings Inc.
Evotec SE
Medpace Holdings Inc.
BioIVT
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →WuXi AppTec Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Labcorp Drug Development (Covance)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →PPD
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Inc. (Thermo Fisher Scientific)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Syneos Health Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Parexel International Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →IQVIA Holdings Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Evotec SE
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Medpace Holdings Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →BioIVT
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Sangamo Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Crown Bioscience Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →GenScript Biotech Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Pharmaron
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,878M by 2033 · 4.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Target Identification and Validation50.3
- High Throughput Screening17.1
- Lead Optimization7.4
- Preclinical Development17.5
- Biomarker Discovery7.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,804M → $2,300M · 3.1%
Europe$1,257M → $1,799M · 4.6%
Asia Pacific$1,148M → $1,794M · 5.7%
Latin America$710.5M → $1,116M · 5.8%
Middle East and Africa$546.5M → $754.3M · 4.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.622026
4.632027
4.652028
4.662029
4.682030
4.692031
4.702032
4.712033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories International Inc.10.9
- WuXi AppTec Co. Ltd.15.5
- Labcorp Drug Development (Covance)10.2
- ICON plc14.7
- PPD9.2
- Inc. (Thermo Fisher Scientific)11.4
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type35.1%
Technology Platform29.9%
Therapeutic Area10.7%
End User24.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.6
- Europe23.2
- Asia Pacific23.1
- Latin America14.4
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | 85 | 78 | 97 | 80 | 94 | 89 | 87 |
| WuXi AppTec Co. Ltd. | 72 | 91 | 75 | 89 | 76 | 71 | 79 |
| Labcorp Drug Development (Covance) | 76 | 73 | 66 | 80 | 64 | 82 | 74 |
| ICON plc | 66 | 69 | 78 | 66 | 61 | 71 | 69 |
| PPD | 62 | 65 | 57 | 76 | 68 | 77 | 68 |
| Inc. (Thermo Fisher Scientific) | 71 | 64 | 52 | 62 | 54 | 47 | 58 |
| Syneos Health Inc. | 58 | 50 | 47 | 51 | 43 | 55 | 51 |
| Parexel International Corporation | 37 | 57 | 47 | 40 | 49 | 43 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories International Inc.
- WuXi AppTec Co. Ltd.
- Labcorp Drug Development (Covance)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| WuXi AppTec Co. Ltd. | ✓ | ✓ | ◐ | ✓ | ◐ | − |
| Labcorp Drug Development (Covance) | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| ICON plc | − | ◐ | ◐ | ◐ | − | ✓ |
| PPD | − | ◐ | − | ◐ | ◐ | ✓ |
| Inc. (Thermo Fisher Scientific) | − | ◐ | ◐ | ✓ | ◐ | ◐ |
| Syneos Health Inc. | − | ◐ | − | − | − | − |
| Parexel International Corporation | − | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Charles River Laboratories International Inc.87
2WuXi AppTec Co. Ltd.79
3Labcorp Drug Development (Covance)74
4ICON plc69
5PPD68
6Inc. (Thermo Fisher Scientific)58
7Syneos Health Inc.51
8Parexel International Corporation46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Charles River Laboratories International Inc.WuXi AppTec Co. Ltd.
Challenger3
Strong scale, closing on the leaders.
Labcorp Drug Development (Covance)ICON plcPPD
Contender1
Focused players with pockets of strength.
Inc. (Thermo Fisher Scientific)
Niche2
Specialists in a single segment or region.
Syneos Health Inc.Parexel International Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Oncology Drug Discovery Services Market — a $72M beachhead inside a $982M market.
Beachhead (SOM)$72Mobtainable near-term
Serviceable (SAM)$389Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Target Identification and Validation
Best fit — highest urgency & budget in Service Type.
Economic buyer81 fit
High Throughput Screening
Strong fit — clear ROI and a fast path to value.
End user68 fit
Lead Optimization
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Technology Platform & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapeutic Area
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel27%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Oncology Drug Discovery Services Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified21%
Evaluation12%
Closed-won7%
$15.9KCAC
$82KLTV
5.2:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Oncology Drug Discovery Services Market is a durable-growth opportunity — $7.41B by 2033, compounding at 7.2%.
TAM · 2025$4.25Btoday
TAM · 2033$7.41Bforecast
CAGR7.2%2027–2033
Cumulative$51.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.41BTotal addressable market
SAM$2.58BServiceable available market
SOM$540MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.2% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.41BLarge & growingTAM by 2033 at 7.2% CAGR
$2.58BServiceable nowreachable with today’s model
$540MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.78BBear4.7% CAGR
$7.41BBase7.2% CAGR
$9.48BBull9.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Technology Platform optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Oncology Drug Discovery Services Market — a $4.75B market by 2033. Plan: grow share from 8.3% to 13.2%.
Market size · 2033$4.75Btotal addressable
Market CAGR4.1%2027–2033
Target share13.2%from 8.3% today
Revenue ambition$627Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.3% | 13.2% | On track |
| Revenue | $392M | $627M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 36.5% | 44.6% | Behind |
| Customer retention | 89.3% | 94.8% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Technology Platform capability
A defensible second engine — invest in Technology Platform to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Technology Platform
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $88M capacity & capability investment
- Greenlight bolt-on M&A in Technology Platform
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskBehind
- Regulatory / policy changeAhead
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Oncology Drug Discovery Services Market conversation — a $10.2B market you can size, segment and defend in minutes.
Market size · 2033$10.2Btotal opportunity
Growth8.7%CAGR to 2033
Addressable buyers1,483+accounts in scope
Typical ROI5.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.7×return on cost, year one
< 2 mopayback period
$59K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Charles River Laboratories International Inc.WuXi AppTec Co. Ltd.Labcorp Drug Development (Covance)ICON plcPPDInc. (Thermo Fisher Scientific)Syneos Health Inc.Parexel International Corporation+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Oncology Drug Discovery Services Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Oncology Drug Discovery Services Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Oncology Companion Diagnostic Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportOncology Clinical Imaging Solutions Market
Market size, share, segmentation and regional forecast.
$563M market · 2025 base year
View reportOncology Blood Testing Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportOncology Based Preclinical CRO Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportOncology Based In-vitro CRO Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportOncology Automation Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportOncology Apoptosis Modulator Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportOncology Ablation Device Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportOncological Phototherapy Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportOnco-hematology Molecular Testing Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportOnchocerciasis Treatment Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportONC Certified EMR Software Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.